CAMBRIDGE, Mass.– QuantHealth, a pioneer in AI-powered clinical trial simulation, today announced a strategic investment from Sanofi Ventures, the venture capital arm of Sanofi. The investment brings QuantHealth’s total funding to $30 million and will accelerate the company’s efforts to expand its digital twin and patient-level simulation technologies to improve drug development.
QuantHealth’s platform allows pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By creating millions of patient-level digital twins, the platform predicts trial outcomes and helps optimize study design to increase success rates, shorten development timelines, and reduce costs.
The collaboration deepens an enterprise-level strategic relationship that supports Sanofi’s broader efforts to integrate advanced AI and digital tools into its global R&D ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will join QuantHealth’s Board of Directors as an observer.
“We’re proud to welcome Sanofi Ventures as an investor and strategic ally in our journey,” said Orr Inbar, CEO and Co-founder of QuantHealth. “Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development.”
“QuantHealth has the potential to transform how clinical trials are designed and optimized,” said Cris De Luca, Partner at Sanofi Ventures. “Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team.”
“At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy,” said Emmanuel Frenehard, Chief Digital Officer at Sanofi. “Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we’re excited to explore this capability together.”
The partnership underscores a shared commitment to advancing drug development through responsible use of artificial intelligence in the life sciences.
